Trinity Biotech zeroes in on CGM 

DUBLIN – Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive financial advisor to support its ongoing strategic realignment, including its increased focus on continuous glucose monitoring technology. As part of this effort, Barclays is now actively assessing how the company’s existing businesses can best align with this new strategic direction. “Over the past year we have focused on proving the technological and market feasibility of building a large scale, innovative global CGM business,” said John Gillard, CEO and president. “Our strong pre-pivotal clinical trial data and the keen market interest for our more affordable, user-focused and sustainable CGM solution gives us confidence that this is a vast and compelling opportunity for Trinity Biotech and our investors. At the same time, our strong execution of the company’s ambitious comprehensive transformation plan is poised to provide us with a portfolio of operating businesses with significantly improved financial prospects. Given this progress, now is the right time to explore how we can strategically allocate capital, optimize our balance sheet, and sharpen our focus on CGM growth.” The successful execution of Trinity Biotech’s comprehensive transformation plan is expected to drive near-term profitability improvements, creating potential opportunities to optimize its portfolio and support CGM-related growth. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide.